🇺🇸 United States Country × Condition
advanced solid tumor Clinical Trials in United States
Active clinical trials for advanced solid tumor with research sites in United States. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 22 // Recruiting: 22 Phases: Phase 1, Phase 1, Phase 2 // Updated: Daily
Total Trials
22
Recruiting Now
22
Country
🇺🇸 United States
Active Trials in United States (22)
NCT06533059 Phase 1
Recruiting
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Enrollment
110 pts
Country
🇺🇸 United States
Alterome Therapeutics, Inc.
View Trial → NCT07269080 Phase 1
Recruiting
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Enrollment
28 pts
Country
🇺🇸 United States
University of Illinois at Chicago
View Trial → NCT06163391 Phase 1
Recruiting
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
Enrollment
40 pts
Country
🇺🇸 United States
SOTIO Biotech AG
View Trial → NCT07284186 Phase 1
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Enrollment
155 pts
Country
🇺🇸 United States
Plexium, Inc.
View Trial → NCT06233942 Phase 1
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Enrollment
308 pts
Country
🇺🇸 United States
BeOne Medicines
View Trial → NCT06997029 Phase 1
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Enrollment
234 pts
Country
🇺🇸 United States
Bristol-Myers Squibb
View Trial → NCT06130254 Phase 1
Recruiting
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Enrollment
52 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT06251310 Phase 1
Recruiting
SW-682 in Advanced Solid Tumors
Enrollment
186 pts
Country
🇺🇸 United States
SpringWorks Therapeutics, Inc.
View Trial → NCT04390737 Phase 1, Phase 2
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
Enrollment
254 pts
Country
🇺🇸 United States
Haihe Biopharma Co., Ltd.
View Trial → NCT05768932 Phase 1
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Enrollment
260 pts
Country
🇺🇸 United States
SillaJen, Inc.
View Trial → NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Enrollment
540 pts
Country
🇺🇸 United States
Daiichi Sankyo
View Trial → NCT06887348
Recruiting
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Enrollment
50 pts
Country
🇺🇸 United States
Replimune Inc.
View Trial → NCT05038150 Phase 1, Phase 2
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
Enrollment
70 pts
Country
🇺🇸 United States
Guangzhou Sinogen Pharmaceutical Co...
View Trial → NCT06132503 Phase 1
Recruiting
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Enrollment
110 pts
Country
🇺🇸 United States
Lantern Pharma Inc.
View Trial → NCT05329103 Phase 1
Recruiting
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Enrollment
65 pts
Country
🇺🇸 United States
Peel Therapeutics Inc
View Trial → NCT05661461 Phase 1
Recruiting
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Enrollment
28 pts
Country
🇺🇸 United States
Aadi Bioscience, Inc.
View Trial → NCT06660654 Phase 2
Recruiting
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Enrollment
200 pts
Country
🇺🇸 United States
Daiichi Sankyo
View Trial → NCT06463340 Phase 1
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Enrollment
52 pts
Country
🇺🇸 United States
Schrödinger, Inc.
View Trial → NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Country
🇺🇸 United States
PMV Pharmaceuticals, Inc
View Trial → NCT05873686 Phase 1
Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Enrollment
140 pts
Country
🇺🇸 United States
Nuvectis Pharma, Inc.
View Trial → NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Country
🇺🇸 United States
Impact Therapeutics, Inc.
View Trial → NCT04890613 Phase 1
Recruiting
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Enrollment
52 pts
Country
🇺🇸 United States
Senhwa Biosciences, Inc.
View Trial → Frequently Asked Questions
How many advanced solid tumor clinical trials are active in United States?
There are currently 22 active clinical trials for advanced solid tumor with sites in United States, of which 22 are actively recruiting patients.
How can I join a advanced solid tumor clinical trial in United States?
To join a advanced solid tumor clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are advanced solid tumor trials in United States?
Active advanced solid tumor trials in United States span Phase 1, Phase 1, Phase 2, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.